Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data KALA BIO, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
6.07
6.36
11.2
3.89
0
0
0
Research and development
25
29
29.3
27.3
18.4
11.5
17.7
18.6
22.1
18.8
Selling, general and administrative
10.9
35.4
65
81.1
105
65
20.6
General and administrative
7.64
10.9
20.6
18.3
23.6
Operating expenses
32.7
39.9
64.7
94.3
103
141
85.6
39.7
41
39.2
Operating income
-32.7
-39.9
-64.7
-88.2
-96.2
-130
-81.7
-39.7
-41
-39.2
Interest expense
0.77
1.02
3.31
8.48
8.59
8.38
7.27
5.81
5.78
3.28
Interest income
0.15
0.53
1.69
2.36
0.49
0.1
0.66
2.71
2.06
1.14
Other non-operating income
-12.4
36.9
-2.54
2.47
12.2
Income tax
0
0
0
0
0
0
0
0
0
0
Net income
-33.2
-42.2
-66.7
-94.3
-104
-143
-44.8
-42.2
-38.5
-27
EBITDA
-32.4
-39.6
-64.4
-87.4
-95.3
-129
-81.2
-39.4
-40.7
-38.8
EPS, basic
-1,388.00
-183.50
-123.16
-136.51
-98.43
-108.32
-29.48
-17.35
-10.15
-3.31
EPS, diluted
-1,388.00
-183.50
-123.16
-136.51
-98.43
-108.32
-29.48
-17.35
-10.15
-3.31
Shares, basic (weighted)
0.02
0.23
0.54
0.69
1.06
1.32
1.52
2.43
3.8
8.15
Shares, diluted (weighted)
0.02
0.23
0.54
0.69
1.06
1.32
1.52
2.43
3.8
8.15
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
45.5
115
183
85.4
77.3
92.1
70.5
50.9
51.2
7.56
Short-term investments
76.3
Receivables
11.6
9.6
15.3
0.2
Inventory
4.1
4.65
5.23
8.64
Other current assets
0.04
0.2
0.48
3.82
3.01
6.2
7.85
1.98
1.62
1.93
Total current assets
45.6
115
177
105
171
124
85.9
52.9
52.8
9.49
Property, plant and equipment
0.59
0.79
2.17
2.7
3.17
2.72
0.4
0.75
0.75
Lease right-of-use assets
0.41
29.6
29.8
27.9
1.3
0.02
2.03
1.69
Total assets
46.3
117
221
154
222
139
86.8
55.9
55.5
9.49
Accounts payable
1
1.2
5.45
2.52
1.72
4.9
2.83
0.92
0.63
0.99
Accrued liabilities
3.99
6.61
11.1
20.9
19
21
8.91
6.02
2.39
0.18
Deferred revenue
4.19
Short-term debt
0.56
6.67
5
10.3
Total current liabilities
5.55
14.9
17
24.8
22.2
37.4
25.7
8.35
17
2.49
Long-term debt
9.1
12
70.2
71.2
72.2
78.9
37.9
34.2
20.1
Lease liabilities
0.55
1.8
1.43
Other non-current liabilities
0.02
0.01
Total liabilities
15.7
26.9
116
125
122
123
67.8
48.4
43.2
2.49
Total debt
9.65
18.9
75
75
75
80
43.3
34
29.3
Paid-in capital
4.37
224
306
325
500
559
606
637
680
702
Retained earnings
-92.1
-134
-201
-295
-400
-542
-587
-629
-668
-695
Other comprehensive income
0
Shareholders' equity
-87.8
89.7
105
29.7
100
16.8
19
7.5
12.3
7
Total equity
-87.8
89.7
105
29.7
100
16.8
19
7.5
12.3
7
Total liabilities and equity
46.3
117
221
154
222
139
86.8
55.9
55.5
9.49
Shares outstanding
0.02
0.5
0.68
0.73
1.19
1.32
1.71
2.76
6.09
0.56
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-33.2
-42.2
-66.7
-94.3
-104
-143
-44.8
-42.2
-38.5
-27
Depreciation and amortization
0.3
0.29
0.35
0.84
0.91
0.98
0.54
0.3
0.26
0.32
Stock-based compensation
2.07
3.57
8.62
9.99
13.3
16.1
7.01
7.46
8.39
7
Change in receivables
-11.6
1.96
-5.76
15.1
0.08
Change in inventory
-3.87
-4.27
-2.37
-6.26
1.71
7.54
Change in payables
-0.34
0.21
4.09
-2.77
-0.92
3.23
-2.08
-1.9
-0.29
0.36
Cash from operations
-27.3
-34.1
-54.1
-92.7
-90.7
-108
-78.9
-27.9
-29.4
-32
Capital expenditures
-0.15
-0.48
-1.58
-1.34
Acquisitions
-4.65
Purchases of investments
-114
-4.99
-9.87
Cash from investing
-0.15
-0.48
-1.58
-1.34
-78.2
70.8
62.7
-0.43
-0.21
-0.02
Debt issued
1.33
10
71.9
77.8
Stock issued
0
30
30
8.43
159
41.2
1.04
18.5
3.39
9.13
Cash from financing
67.2
104
124
8.98
161
42.6
-7.94
8.51
29.9
-11.6
Net change in cash
39.7
69.1
68.4
-85.1
-8.28
5.12
-24.1
-19.9
0.29
-43.6
Free cash flow
-27.5
-34.6
-55.7
-94.1
Interest paid
0.68
0.86
3.04
7.52
7.53
6.84
5.96
4.62
4.61
2.7
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.48 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-111.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-95.3%
Net income / average total assets.
Return on invested capital (ROIC)
-188.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-43.3%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-28.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-41.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-82.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-52.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-46.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
114.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
75.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
50.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
6.88x
Current assets / current liabilities.
Quick ratio
4.70x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.70x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Operating cash flow per share
-$267.84
Cash from operations / diluted weighted shares.
Book value per share
$0.47
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.02x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.02x
Market cap / tangible book value, when positive.
Earnings yield
-109.5%
Net income / market cap (the inverse of P/E).
What was KALA BIO, Inc.'s revenue in fiscal 2025?
KALA BIO, Inc. reported revenue of $0.0 for fiscal 2025.
Was KALA BIO, Inc. profitable in fiscal 2025?
No. It reported a net loss of $27.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.